BioAtla Files 8-K: Material Agreement, Equity Sales
Ticker: BCAB · Form: 8-K · Filed: Dec 31, 2025 · CIK: 1826892
Sentiment: neutral
Topics: material-agreement, equity-sale, regulation-fd
TL;DR
BioAtla dropped an 8-K detailing a new material deal and stock sales. Keep an eye on this.
AI Summary
BioAtla, Inc. filed an 8-K on December 31, 2025, reporting on events that occurred on December 30, 2025. The filing indicates an entry into a material definitive agreement, unregistered sales of equity securities, and a Regulation FD disclosure. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing by BioAtla, Inc. signals significant corporate activity, including a new material agreement and equity transactions, which could impact its financial standing and strategic direction.
Risk Assessment
Risk Level: medium — The filing involves unregistered sales of equity securities and a material definitive agreement, which can introduce financial and operational risks.
Key Players & Entities
- BioAtla, Inc. (company) — Registrant
- December 30, 2025 (date) — Date of earliest event reported
- December 31, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 858-558-0708 (phone_number) — Business phone number
FAQ
What is the nature of the material definitive agreement entered into by BioAtla, Inc.?
The filing indicates an entry into a material definitive agreement, but the specific details of this agreement are not provided in the summary information.
What type of equity securities were sold in the unregistered sales reported?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in the provided summary.
What is the purpose of the Regulation FD Disclosure mentioned in the filing?
The filing notes a Regulation FD Disclosure, which is typically made to ensure that material non-public information is broadly disseminated to the public, but the content of this disclosure is not specified.
When was the 8-K report filed and what is the earliest event date reported?
The 8-K report was filed on December 31, 2025, and the earliest event reported is dated December 30, 2025.
What is BioAtla, Inc.'s principal executive office address?
BioAtla, Inc.'s principal executive offices are located at 11085 Torreyana Road, San Diego, California, 92121.
Filing Stats: 1,730 words · 7 min read · ~6 pages · Grade level 15.8 · Accepted 2025-12-31 07:15:24
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BCAB Nasdaq Cap
- $40 million — in the SPV in exchange for an aggregate $40 million. The Company expects to use the gross p
- $5 million — 2026, in which the Company will receive $5 million for the sale of the SPV's common units
- $35 m — o completion of a financing of at least $35 million, Inversagen AI has agreed to purc
- $35 million — of the SPV common units in exchange for $35 million. The Investment Agreement contains repr
Filing Documents
- d20340d8k.htm (8-K) — 36KB
- d20340dex991.htm (EX-99.1) — 25KB
- 0001193125-25-337646.txt ( ) — 182KB
- bcab-20251230.xsd (EX-101.SCH) — 3KB
- bcab-20251230_lab.xml (EX-101.LAB) — 17KB
- bcab-20251230_pre.xml (EX-101.PRE) — 11KB
- d20340d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, statements we make regarding the expected gross proceeds from the transactions, the timing and completion of the transaction and the anticipated use of proceeds therefrom, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the Company's ability to continue as a going concern and that it will need additional funding to continue development of its CAB technology platform and its CAB product candidates; the risk that preliminary or interim clinical results may not be indicative of results from later cohorts or larger populations; potential delays in clinical and preclinical trials; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; the Company's dependence on the success of its CAB technology platform; its ability to enroll patients in its ongoing and future clinical trials; the successful selection and prioriti
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated December 31, 2025 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioAtla, Inc. Date: December 31, 2025 By: /s/ Richard A. Waldron Richard A. Waldron Chief Financial Officer